Arachidonic acid synergizes with aspirin preventing myocardial ischaemia–reperfusion injury and mitigates bleeding risk
Cardiovascular Research · 2025
DOI: 10.1093/cvr/cvae254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Shaletanati Talabieke und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cardiovascular Disease, Clinical Pharmacology Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Ac…. Hauptthemen laut MEDLINE: Aspirin, Arachidonic Acid, Myocardial Reperfusion Injury, Gastrointestinal Hemorrhage. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Aims
The therapeutic efficacy of coronary revascularization is compromised by myocardial ischaemia–reperfusion (MI/R) injury. Higher levels of circulating arachidonic acid (AA) are reportedly associated with lower risk of cardiovascular disease. The cyclooxygenase (COX) pathway metabolizes AA into prostaglandins (PGs) and the platelet-activating thromboxane A2 (TXA2), which is inhibited by aspirin. We aimed to explore whether AA or its combination with aspirin modulates MI/R injury and aspirin-caused gastric bleeding. Methods and results Mice were subjected to 30-min coronary artery ligation followed by reperfusion. AA reduced MI/R injury in mice, and its combination with aspirin provided further cardioprotection. Aspirin inhibited MI/R-triggered platelet activation and ameliorated microvascular obstruction immediately upon reperfusion, whereas AA improved microvascular perfusion at a later stage of reperfusion, coinciding with increased coronary vasodilatation. Co-administration of AA and aspirin markedly reduced cardiac neutrophil infiltration and vascular permeability and improved microcirculation. AA increased urinary metabolites of PGI2 and PGE2, not TXA2, and this selective augmentation was further enhanced by co-treatment with aspirin. Elevation in PGI2 and PGE2 correlated with reduced infarction and improved ventricular function, and inhibiting COX-2 attenuated the synergistic cardioprotection. Furthermore, oral administration of AA with aspirin after reperfusion provided a maximal cardioprotection and abolished aspirin-caused gastric bleeding.
Conclusion
AA synergizes with aspirin in protecting against MI/R injury, while minimizing the related bleeding risk, a major concern for patients with acute myocardial infarction. This is attributable to the selective augmentation of PGI2 and PGE2 that is amplified by TXA2 suppression by aspirin, underscoring improved microcirculation and ameliorated inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cardiovascular Disease, Clinical Pharmacology Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 167 Beilishi…
- Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College,…
- Tianjin Key Laboratory of Metabolic Diseases, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Center for Cardiovascular Diseases, Research Center of Basic Medical Sciences…
- Department of Systems Pharmacology and Translational Therapeutics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- National Health Commission Cardiovascular Disease Regenerative Medicine Research Key Laboratory, Central China Subcenter of National Center for Cardiovascular Diseases, Henan Cardiovascular Disease Center, Fuwai Central…
ORCID-Profile: Miao Wang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- CAMS
- Innovation Fund for Medical Sciences
- Central Research Institute Fund of CAMS
- Fuwai Hospital
Zitieren
APA
Talabieke, S., Yang, X., Yang, J., Wan, Q., Zhu, D., Rao, H., Wu, Y., Chen, Z., Li, H., Xu, P., Chen, H., Liu, D. P., Zhang, X., FitzGerald, G. A., & Wang, M. (2025). Arachidonic acid synergizes with aspirin preventing myocardial ischaemia–reperfusion injury and mitigates bleeding risk. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae254
Vancouver
Talabieke S, Yang X, Yang J, Wan Q, Zhu D, Rao H, et al. Arachidonic acid synergizes with aspirin preventing myocardial ischaemia–reperfusion injury and mitigates bleeding risk. Cardiovascular Research. 2025. doi:10.1093/cvr/cvae254
BibTeX
@article{Talabieke2025,
author = {Talabieke, Shaletanati and Yang, Xuejian and Yang, Jianfeng and Wan, Qing and Zhu, Dekun and Rao, Haojie and Wu, Yifei and Chen, Zengrong and Li, Huihui and Xu, Pengfei and Chen, Hong and Liu, De-Pei and Zhang, Xu and FitzGerald, Garret A and Wang, Miao},
title = {Arachidonic acid synergizes with aspirin preventing myocardial ischaemia–reperfusion injury and mitigates bleeding risk},
journal = {Cardiovascular Research},
year = {2025},
doi = {10.1093/cvr/cvae254}
}
EUVIMED